Karim Fizazi
AuthID: R-00H-N9T
1
TÃTULO: Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
AUTORES: Fizazi, Karim; Shore, Neal D.; Smith, Matthew Raymond; Ramos, Rodrigo; Jones, Robert J.; Niegisch, Guenter; Vjaters, Egils; Ortiz, Jorge A.; Liang, Steve; Wang, Yuan; Srinivasan, Shankar; Sarapohja, Toni; Verholen, Frank;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 6
AUTORES: Fizazi, Karim; Shore, Neal D.; Smith, Matthew Raymond; Ramos, Rodrigo; Jones, Robert J.; Niegisch, Guenter; Vjaters, Egils; Ortiz, Jorge A.; Liang, Steve; Wang, Yuan; Srinivasan, Shankar; Sarapohja, Toni; Verholen, Frank;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 6
INDEXADO EM: 
WOS
WOS2
TÃTULO: Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases
AUTORES: Luis Costa; Karim Fizazi; Fred Saad; Janet Elizabeth Brown; Roger Von Moos; Stephane Oudard; Cora N Sternberg; Vinod Ganju; Kurt Miller; Huei Wang; Tapan Maniar; Ada Braun;
PUBLICAÇÃO: 2013, FONTE: 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, NÚMERO: 15
AUTORES: Luis Costa; Karim Fizazi; Fred Saad; Janet Elizabeth Brown; Roger Von Moos; Stephane Oudard; Cora N Sternberg; Vinod Ganju; Kurt Miller; Huei Wang; Tapan Maniar; Ada Braun;
PUBLICAÇÃO: 2013, FONTE: 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, NÚMERO: 15
INDEXADO EM: WOS
WOS